Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc., sold 1,800 shares of common stock to satisfy tax withholding obligations related to vested performance stock units.

Summary

• Masaru Matsuda, SVP General Counsel and Corporate Secretary of Arcutis Biotherapeutics, Inc. (ARQT), reported a transaction on May 28, 2025.
• The transaction involved the sale of 1,800 shares of Arcutis Biotherapeutics Common Stock.
• The shares were sold at a weighted average price of $13.7814 per share, with prices ranging from $13.64 to $14.16.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Performance Stock Units (PSUs) granted on January 3, 2022.
• Following this transaction, Mr. Matsuda beneficially owns 202,599 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations, not indicative of a change in the insider's view on the company's prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a sale to cover tax obligations, which is common practice in executive compensation plans involving equity awards. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of 1,800 shares by an executive is a minor transaction and is unlikely to have a significant direct impact on the share price or shareholder value. It is a standard part of equity compensation management.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Stock Sale, Tax Withholding, Performance Stock Units, Executive Compensation